Table 4 Associations of high versus low/no mutations in tumor and blood samples with survival, using multivariable-adjusted Cox proportional hazards regression

Baseline

 KRAS in tumor

50.81 (2.89–894.46)

0.865 (0.791–0.939)

0.007

2.62 (0.61–11.21)

0.194

0.871 (0.804–0.938)

 KRAS in blood

5281.33 (49.98–558,121.20)

0.864 (0.796–0.932)

< 0.001

6.11 (0.68–54.88)

0.106

0.866 (0.797–0.935)

 TP53 in tumor

5.12 (0.78–33.84)

0.828 (0.739–0.917)

0.090

1.00 (0.31–3.20)

0.999

0.858 (0.782–0.934)

 TP53 in blood

33.58 (1.33–849.52)

0.833 (0.751–0.915)

0.033

3.02 (0.43–21.23)

0.266

0.859 (0.785–0.933)

 CDKN2A in tumor

0.76 (0.05–12.25)

0.816 (0.718–0.914)

0.849

0.63 (0.06–6.77)

0.701

0.859 (0.786–0.932)

 CDKN2A in blood

3.84 (0.23–64.48)

0.822 (0.722–0.922)

0.350

12.82 (1.55–106.11)

0.018

0.873 (0.799–0.947)

 SMAD4 in tumor

1.33 (0.18–9.92)

0.818 (0.732–0.904)

0.779

0.69 (0.10–4.72)

0.706

0.862 (0.784–0.940)

 SMAD4 in blood

127.19 (2.60–6211.68)

0.851 (0.754–0.948)

0.015

34.59 (1.76–680.21)

0.020

0.868 (0.783–0.953)

 ARID1A in tumor

NE

NE

 ARID1A in blood

20.11 (0.78–521.34)

0.846 (0.729–0.963)

0.071

4.97 (0.30–83.58)

0.266

0.858 (0.778–0.938)

2nd measurement

 KRAS in blood

180.62 (0.05–657561.60)

0.865 (0.830–0.900)

0.214

2.74 (< 0.01–20.56)

0.557

0.874 (0.827–0.921)

 TP53 in blood

1.28 (0.01–217.63)

0.862 (0.839–0.885)

0.925

0.05 (< 0.01–2.65)

0.138

0.882 (0.863–0.901)

 CDKN2A in blood

140.24 (0.03–790450.30)

0.868 (0.830–0.906)

0.262

359.82 (0.03–4515432.00)

0.222

0.867 (0.825–0.909)

3rd measurement

 KRAS in blood

7.41 (0.42–132.48)

0.850 (0.823–0.877)

0.173

2.73 (0.40–18.66)

0.306

0.879 (0.826–0.932)

 TP53 in blood

4.72 (< 0.01–5037.12)

0.845 (0.817–0.873)

0.663

3.02 (0.03–301.50)

0.638

0.872 (0.844–0.900)

 CDKN2A in blood

NE

NE